PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
8.26%
Revenue growth exceeding 1.5x Medical - Pharmaceuticals median of 0.84%. Joel Greenblatt would investigate if growth quality matches quantity.
6.98%
Cost growth of 6.98% versus flat Medical - Pharmaceuticals costs. Walter Schloss would verify cost control.
13.78%
Gross profit growth exceeding 1.5x Medical - Pharmaceuticals median of 1.05%. Joel Greenblatt would investigate competitive advantages.
5.09%
Margin change of 5.09% versus flat Medical - Pharmaceuticals margins. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
11.73%
Other expenses change of 11.73% versus flat Medical - Pharmaceuticals costs. Walter Schloss would verify efficiency.
2.58%
Operating expenses growth exceeding 1.5x Medical - Pharmaceuticals median of 0.86%. Jim Chanos would check for waste.
6.26%
Total costs growth exceeding 1.5x Medical - Pharmaceuticals median of 1.37%. Jim Chanos would check for waste.
No Data
No Data available this quarter, please select a different quarter.
6.03%
D&A growth exceeding 1.5x Medical - Pharmaceuticals median of 1.75%. Jim Chanos would check for overinvestment.
49.01%
EBITDA growth exceeding 1.5x Medical - Pharmaceuticals median of 7.34%. Joel Greenblatt would investigate advantages.
37.64%
EBITDA margin growth exceeding 1.5x Medical - Pharmaceuticals median of 1.20%. Joel Greenblatt would investigate advantages.
78.82%
Income change of 78.82% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
65.17%
Margin change of 65.17% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
22.22%
Other expenses growth while Medical - Pharmaceuticals reduces costs. Peter Lynch would examine differences.
65.97%
Pre-tax income growth while Medical - Pharmaceuticals declines. Peter Lynch would examine advantages.
53.30%
Margin change of 53.30% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
73.98%
Tax expense growth while Medical - Pharmaceuticals reduces burden. Peter Lynch would examine differences.
59.23%
Net income growth while Medical - Pharmaceuticals declines. Peter Lynch would examine advantages.
47.08%
Margin change of 47.08% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
55.38%
EPS change of 55.38% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
55.38%
Diluted EPS change of 55.38% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
-0.00%
Share count reduction while Medical - Pharmaceuticals median is 0.01%. Seth Klarman would investigate strategy.
-0.00%
Diluted share reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate strategy.